News stories about Organovo (NASDAQ:ONVO) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Organovo earned a news impact score of 0.11 on Accern’s scale. Accern also assigned press coverage about the medical research company an impact score of 45.2860510239233 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Shares of Organovo (NASDAQ:ONVO) traded down $0.01 during trading hours on Wednesday, reaching $1.38. The company had a trading volume of 1,276,800 shares, compared to its average volume of 1,082,958. Organovo has a 12 month low of $1.32 and a 12 month high of $4.08.
Organovo (NASDAQ:ONVO) last announced its earnings results on Thursday, November 9th. The medical research company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. Organovo had a negative return on equity of 65.63% and a negative net margin of 923.89%. The company had revenue of $1.36 million for the quarter, compared to analyst estimates of $1.38 million. The firm’s quarterly revenue was down 1.4% compared to the same quarter last year. equities analysts predict that Organovo will post -0.36 earnings per share for the current fiscal year.
Several brokerages have weighed in on ONVO. Jefferies Group reiterated a “buy” rating and issued a $4.00 target price on shares of Organovo in a report on Tuesday, September 26th. Zacks Investment Research upgraded Organovo from a “hold” rating to a “buy” rating and set a $2.25 target price for the company in a report on Wednesday, October 11th. Raymond James Financial cut Organovo from an “outperform” rating to a “market perform” rating and set a $5.00 target price for the company. in a report on Friday, November 10th. BTIG Research restated a “buy” rating and set a $3.00 price objective on shares of Organovo in a research note on Thursday, November 16th. Finally, Citigroup cut Organovo to a “market perform” rating in a research note on Friday, November 10th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company’s stock. Organovo currently has a consensus rating of “Hold” and a consensus price target of $3.60.
WARNING: This news story was originally posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are accessing this news story on another publication, it was illegally copied and republished in violation of international copyright & trademark law. The legal version of this news story can be read at https://www.truebluetribune.com/2017/12/13/organovo-onvo-receives-daily-news-impact-rating-of-0-11.html.
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.